Preclinical study demonstrates inhibition of colorectal cancer stem cells by a novel benzenesulfonamide derivative, suggesting therapeutic potential against colorectal tumors.
Key Points
Design and synthesize benzenesulfonamide derivatives targeting colorectal cancer stem cells through inhibition of the Wnt/β-catenin signaling pathway.
Designed and synthesized a series of benzenesulfonamide derivatives based on the structural features of the β-catenin/TCF4 inhibitor LF3 and a naphthoquinone moiety.
Evaluated the compounds for anti-proliferative and anti-cancer stem cell activity in vitro and in vivo using colorectal cancer xenograft models.
Identified compound 3gg as an active agent exhibiting anti-proliferation and anti-colorectal cancer stem cell properties via regulation of the Wnt/β-catenin pathway in vitro.
Confirmed that compound 3gg inhibits colorectal cancer stem cell activity through Wnt/β-catenin pathway modulation in animal xenograft models.